CEBP Grants Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Epidemiology Biomarkers & Prevention 17, 3208, November 1, 2008. doi: 10.1158/1055-9965.EPI-08-0512
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data, Poynter, et al.
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poynter, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poynter, J. N.

Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening

Jenny N. Poynter1, Kimberly D. Siegmund1, Daniel J. Weisenberger2, Tiffany I. Long2, Stephen N. Thibodeau3, Noralane Lindor4, Joanne Young5, Mark A. Jenkins6, John L. Hopper6, John A. Baron7, Dan Buchanan5, Graham Casey1, A. Joan Levine1, Loïc Le Marchand8, Steven Gallinger9, Bharati Bapat10, John D. Potter11, Polly A. Newcomb11, Robert W. Haile1, Peter W. Laird2 for the Colon Cancer Family Registry Investigators

Departments of 1 Preventive Medicine and 2 Surgery and Biochemistry and Molecular Biology, University of Southern California, Los Angeles, California; Departments of 3 Laboratory Medicine and Pathology and 4 Medical Genetics, Mayo Clinic, Rochester, Minnesota; 5 Familial Cancer Laboratory, Queensland Institute of Medical Research, Queensland, Australia; 6 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Australia; 7 Department of Medicine, Dartmouth Medical School, Lebanon, New Hampshire; 8 Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii; 9 Cancer Care Ontario and 10 Department of Pathology and Lab Medicine, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, University of Toronto, Toronto, Ontario, Canada; and 11 Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington

Requests for reprints: Peter W. Laird, Departments of Surgery and of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, NOR 6418, Los Angeles, CA 90033-9176. Phone: 323-865-0650; Fax: 323-865-0158. E-mail: plaird{at}usc.edu

Microsatellite instability (MSI) occurs in 10% to 20% of colorectal cancers (CRC) and has been attributed to both MLH1 promoter hypermethylation and germline mutation in the mismatch repair (MMR) genes. We present results from a large population- and clinic-based study of MLH1 methylation, immunohistochemistry, and MMR germline mutations that enabled us to (a) estimate the prevalence of MMR germline mutations and MLH1 methylation among MSI-H cases and help us understand if all MSI-H CRC is explained by these mechanisms and (b) estimate the associations between MLH1 methylation and sex, age, and tumor location within the colon. MLH1 methylation was measured in 1,061 population-based and 172 clinic-based cases of CRC. Overall, we observed MLH1 methylation in 60% of population-based MSI-H cases and in 13% of clinic-based MSI-H cases. Within the population-based cases with MMR mutation screening and conclusive immunohistochemistry results, we identified a molecular event in MMR in 91% of MSI-H cases: 54% had MLH1 methylation, 14% had a germline mutation in a MMR gene, and 23% had immunohistochemistry evidence for loss of a MMR protein. We observed a striking age difference, with the prevalence of a MMR germline mutation more than 4-fold lower and the prevalence of MLH1 methylation more than 4-fold higher in cases diagnosed after the age of 50 years than in cases diagnosed before that age. We also determined that female sex is an independent predictor of MLH1 methylation within the MSI-H subgroup. These results reinforce the importance of distinguishing between the underlying causes of MSI in studies of etiology and prognosis. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3208–15)




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Ogino, K. Shima, K. Nosho, N. Irahara, Y. Baba, B. M. Wolpin, E. L. Giovannucci, J. A. Meyerhardt, and C. S. Fuchs
A Cohort Study of p27 Localization in Colon Cancer, Body Mass Index, and Patient Survival
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1849 - 1858.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
H. T. Lynch, Z. Gatalica, and J. Knezetic
Molecular Genetics and Hereditary Colorectal Cancer: Resolution of the Diagnostic Dilemma of Hereditary Nonpolyposis Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer Type X, and Multiple Polyposis Syndromes
ASCO Educational Book, January 1, 2009; 2009(1): 221 - 226.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.